US7605238B2
(en)
*
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
CA2589418A1
(en)
*
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
KR20120011898A
(ko)
|
2000-02-10 |
2012-02-08 |
아보트 러보러터리즈 |
사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
AU2002231368C1
(en)
|
2001-01-05 |
2018-08-16 |
Amgen Fremont Inc. |
Antibodies to insulin-like growth factor I receptor
|
RS20110024A
(en)
|
2001-04-26 |
2011-08-31 |
Biogen Idec Ma Inc. |
ANTIBODIES THAT BLOCK CRIPTO AND USE IT
|
JP2005519580A
(ja)
|
2001-05-16 |
2005-07-07 |
アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ |
非ヒト動物由来のヒト抗肺炎球菌抗体
|
IL149701A0
(en)
*
|
2001-05-23 |
2002-11-10 |
Pfizer Prod Inc |
Use of anti-ctla-4 antibodies
|
DE60235989D1
(de)
|
2001-06-26 |
2010-05-27 |
Amgen Fremont Inc |
Antikörper gegen opgl
|
AU2006228095B2
(en)
*
|
2001-10-11 |
2010-11-04 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
MXPA04009418A
(es)
|
2002-03-29 |
2005-06-08 |
Schering Corp |
Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
|
NZ536420A
(en)
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
AU2003260871A1
(en)
*
|
2002-09-30 |
2004-04-19 |
Pfizer Products Inc. |
Hybridomas producing high levels of human sequence antibody
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
WO2005019270A2
(en)
*
|
2003-08-14 |
2005-03-03 |
Dyax Corp. |
Endotheliase-2 ligands
|
AR045563A1
(es)
*
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
MX350383B
(es)
|
2004-01-09 |
2017-09-04 |
Pfizer |
Anticuerpos contra madcam.
|
CN1964739A
(zh)
*
|
2004-03-26 |
2007-05-16 |
辉瑞产品公司 |
抗ctla-4抗体的用途
|
US7494779B2
(en)
|
2004-06-14 |
2009-02-24 |
Li-Te Chin |
Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
|
DK2287195T3
(da)
|
2004-07-01 |
2019-08-19 |
Innate Pharma |
Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
|
CA2573821A1
(en)
|
2004-07-16 |
2006-01-26 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
|
WO2006056464A2
(en)
*
|
2004-11-26 |
2006-06-01 |
Pieris Ag |
Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
|
AU2014240252B2
(en)
*
|
2005-03-08 |
2016-10-06 |
Pfizer Products Inc |
Anti-CTLA-4 Antibody Compositions
|
AU2012200203B2
(en)
*
|
2005-03-08 |
2014-07-03 |
Pfizer Products Inc. |
Anti-CTLA-4 Antibody Compositions
|
US9487581B2
(en)
*
|
2005-03-08 |
2016-11-08 |
Pfizer Inc. |
Anti-CTLA-4 antibody compositions
|
AU2006227879A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Therapy of prostate cancer with CTLA4 antibodies and hormonal therapy
|
JP2006265155A
(ja)
*
|
2005-03-23 |
2006-10-05 |
Link Genomics Kk |
癌の免疫療法
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
AP2007004243A0
(en)
|
2005-04-25 |
2007-12-31 |
Pfizer |
Antibodies to myostatin
|
CA2604357C
(en)
|
2005-04-26 |
2012-01-17 |
Pfizer Inc. |
P-cadherin antibodies
|
WO2006117910A1
(ja)
|
2005-04-28 |
2006-11-09 |
Mochida Pharmaceutical Co., Ltd. |
抗血小板膜糖蛋白質ⅵモノクローナル抗体
|
JP5224707B2
(ja)
*
|
2005-04-28 |
2013-07-03 |
持田製薬株式会社 |
抗血小板膜糖蛋白質viモノクローナル抗体
|
EP1896582A4
(en)
|
2005-05-09 |
2009-04-08 |
Ono Pharmaceutical Co |
HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH 1 (MP-1) AND METHODS FOR TREATING CANCER USING ANTI-MP-1 ANTIBODIES ALONE OR ASSOCIATED WITH OTHER IMMUNOTHERAPIES
|
LT2397156T
(lt)
|
2005-06-08 |
2017-02-27 |
Dana-Farber Cancer Institute, Inc. |
Būdai ir kompozicijos, skirti nuolatinių infekcijų ir vėžio gydymui inhibuojant užprogramuotos ląstelės mirties-1 (pd-1) kelią
|
NZ565311A
(en)
*
|
2005-07-07 |
2009-10-30 |
Pfizer |
Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
|
CN100443503C
(zh)
*
|
2005-07-18 |
2008-12-17 |
四川大学华西医院 |
人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
|
EP2500355A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
SG2014010029A
(en)
|
2005-08-19 |
2014-08-28 |
Abbott Lab |
Dual variable domain immunoglobin and uses thereof
|
AU2006297571B2
(en)
|
2005-09-07 |
2012-03-15 |
Amgen Fremont Inc. |
Human monoclonal antibodies to activin receptor-like kinase-1
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
US8906864B2
(en)
|
2005-09-30 |
2014-12-09 |
AbbVie Deutschland GmbH & Co. KG |
Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
|
CN101300024A
(zh)
|
2005-11-08 |
2008-11-05 |
米德列斯公司 |
对于与免疫刺激性治疗抗体治疗有关的小肠结肠炎的TNF-α阻断剂治疗
|
AU2006319358B2
(en)
|
2005-11-30 |
2012-01-19 |
AbbVie Deutschland GmbH & Co. KG |
Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
|
RS53270B2
(sr)
|
2005-11-30 |
2018-05-31 |
Abbvie Deutschland |
Monoklonalna antitela protiv amiloidnog beta proteina i njihova upotreba
|
JP2009518446A
(ja)
|
2005-12-07 |
2009-05-07 |
メダレックス インコーポレーティッド |
Ctla−4抗体投与量漸増レジメン
|
JP5093097B2
(ja)
|
2006-03-03 |
2012-12-05 |
小野薬品工業株式会社 |
細胞表面機能分子の細胞外領域多量体
|
EP2013348A4
(en)
|
2006-03-30 |
2009-09-02 |
Univ California |
METHODS AND COMPOSITIONS FOR LOCALIZED SECRETION OF ANTI-CTLA-4 ANTIBODIES
|
US7919079B2
(en)
*
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
MX2008012754A
(es)
|
2006-04-07 |
2009-04-27 |
Us Gov Health & Human Serv |
Composiciones de anticuerpos y metodos para tratamiento de enfermedad neoplastica.
|
ES2613957T3
(es)
|
2006-08-04 |
2017-05-29 |
Medimmune Limited |
Anticuerpos contra ERBB2
|
MY188368A
(en)
|
2006-09-08 |
2021-12-06 |
Abbott Lab |
Interleukin-13 binding proteins
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2486928A1
(en)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
CA2680549A1
(en)
|
2007-03-12 |
2008-09-18 |
Alan D. D'andrea |
Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
|
WO2008123999A2
(en)
|
2007-04-02 |
2008-10-16 |
Amgen Fremont Inc. |
Anti-ige antibodies
|
EP2175884B8
(en)
|
2007-07-12 |
2017-02-22 |
GITR, Inc. |
Combination therapies employing gitr binding molecules
|
BRPI0817233A2
(pt)
|
2007-09-28 |
2012-11-06 |
Intrexon Corp |
construções terapêuticas de gene de trca e bireatores para a expressão de moléculas bioterapêuticas, e usos das mesmas
|
DK2222697T3
(da)
|
2007-11-01 |
2013-03-11 |
Perseid Therapeutics Llc |
Immunsuppressive polypeptider og nukleinsyrer
|
PE20091269A1
(es)
|
2007-12-14 |
2009-09-09 |
Medarex Inc |
Moleculas de union al receptor ox40 humano
|
US8449886B2
(en)
|
2008-01-08 |
2013-05-28 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
|
WO2009100140A1
(en)
*
|
2008-02-04 |
2009-08-13 |
Medarex, Inc. |
Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
ES2579554T3
(es)
|
2008-05-09 |
2016-08-12 |
Abbvie Deutschland Gmbh & Co Kg |
Anticuerpos para el receptor de productos terminales de glicación avanzada (RAGE) y usos de los mismos
|
CA2725666A1
(en)
|
2008-06-03 |
2009-12-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
RU2010153580A
(ru)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
JP5674654B2
(ja)
|
2008-07-08 |
2015-02-25 |
アッヴィ・インコーポレイテッド |
プロスタグランジンe2二重可変ドメイン免疫グロブリンおよびその使用
|
CN104829718A
(zh)
|
2008-07-08 |
2015-08-12 |
艾伯维公司 |
前列腺素e2结合蛋白及其用途
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
ES2658117T3
(es)
|
2008-08-18 |
2018-03-08 |
Pfizer Inc. |
Anticuerpos anti-CCR2
|
KR101012267B1
(ko)
*
|
2008-08-29 |
2011-02-08 |
주식회사 세이프로드 |
파손이 방지되는 차선규제봉 및 차선규제봉 시공방법
|
US8475790B2
(en)
|
2008-10-06 |
2013-07-02 |
Bristol-Myers Squibb Company |
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
|
EP2387627B1
(en)
|
2009-01-15 |
2016-03-30 |
Adaptive Biotechnologies Corporation |
Adaptive immunity profiling and methods for generation of monoclonal antibodies
|
US8835610B2
(en)
|
2009-03-05 |
2014-09-16 |
Abbvie Inc. |
IL-17 binding proteins
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
ES2629167T3
(es)
|
2009-07-20 |
2017-08-07 |
Bristol-Myers Squibb Company |
Combinación de anticuerpo anti-CTLA4 con etopósido para el tratamiento sinérgico de enfermedades proliferativas
|
PE20121647A1
(es)
|
2009-08-29 |
2012-12-31 |
Abbvie Inc |
Proteinas terapeuticas de union a dll4
|
TW201119673A
(en)
|
2009-09-01 |
2011-06-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
AU2010308030B2
(en)
|
2009-10-12 |
2014-05-29 |
Pfizer Inc. |
Cancer treatment
|
TW201119676A
(en)
|
2009-10-15 |
2011-06-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
CA2780069C
(en)
|
2009-12-08 |
2018-07-17 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
|
SG10201501562VA
(en)
|
2010-03-02 |
2015-04-29 |
Abbvie Inc |
Therapeutic dll4 binding proteins
|
MX336196B
(es)
|
2010-04-15 |
2016-01-11 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
HUE033063T2
(hu)
|
2010-05-14 |
2017-11-28 |
Abbvie Inc |
IL-1 kötõ fehérjék
|
US20130064831A1
(en)
|
2010-05-17 |
2013-03-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
CA2807014A1
(en)
|
2010-08-03 |
2012-02-09 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2012024187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
US9505829B2
(en)
|
2010-08-19 |
2016-11-29 |
Zoetis Belgium S.A. |
Anti-NGF antibodies and their use
|
CA2809433A1
(en)
|
2010-08-26 |
2012-03-01 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
EP2646552B1
(en)
*
|
2010-12-02 |
2017-07-05 |
Pieris Pharmaceuticals GmbH |
Muteins of human lipocalin 2 with affinity for ctla-4
|
MX348152B
(es)
|
2010-12-14 |
2017-06-02 |
Nat Univ Singapore |
Anticuerpo monoclonal humano con especificidad para el virus del dengue serotipo 1 proteina e y sus usos.
|
RU2627171C2
(ru)
|
2010-12-21 |
2017-08-03 |
Эббви Инк. |
Il-1 альфа и бета биспецифические иммуноглобулины с двойными вариабельными доменами и их применение
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
MX2014000531A
(es)
|
2011-07-13 |
2014-12-05 |
Abbvie Inc |
Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
|
WO2013013029A1
(en)
|
2011-07-19 |
2013-01-24 |
The Board Of Trustees Of The University Of Illinois |
Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
|
MX359314B
(es)
|
2011-08-30 |
2018-09-25 |
Astex Pharmaceuticals Inc Star |
Formulaciones derivadas de decitabina.
|
WO2013063114A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Immunobinders directed against tnf
|
AR088513A1
(es)
|
2011-10-24 |
2014-06-18 |
Abbvie Inc |
Inmunoenlazantes dirigidos contra esclerostina
|
CN104271599A
(zh)
|
2011-11-08 |
2015-01-07 |
辉瑞公司 |
使用抗m-csf抗体治疗炎性疾病的方法
|
CA2855570A1
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
US10118958B2
(en)
|
2011-12-14 |
2018-11-06 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
BR112014015851A2
(pt)
|
2011-12-30 |
2019-09-24 |
Abbvie Inc |
proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
|
ES2676725T3
(es)
|
2012-01-27 |
2018-07-24 |
AbbVie Deutschland GmbH & Co. KG |
Composición y método para el diagnóstico y el tratamiento de enfermedades asociadas con la degeneración de las neuritas
|
US20150110779A1
(en)
|
2012-03-15 |
2015-04-23 |
Bristol-Myers Squibb Company |
Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
|
US20150079100A1
(en)
|
2012-03-23 |
2015-03-19 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla-4 antibodies
|
US9534059B2
(en)
|
2012-04-13 |
2017-01-03 |
Children's Medical Center Corporation |
TIKI inhibitors
|
PE20142406A1
(es)
|
2012-05-04 |
2015-01-23 |
Pfizer |
Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
|
US20150118244A1
(en)
|
2012-05-10 |
2015-04-30 |
Bristol-Myers Squibb Company |
Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
|
AU2013263076B2
(en)
|
2012-05-15 |
2017-08-31 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
JP6629069B2
(ja)
|
2012-06-06 |
2020-01-15 |
ゾエティス・エルエルシー |
イヌ化抗ngf抗体およびその方法
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
US9670276B2
(en)
|
2012-07-12 |
2017-06-06 |
Abbvie Inc. |
IL-1 binding proteins
|
CA2882745C
(en)
*
|
2012-08-23 |
2022-03-29 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 158p1d7 proteins
|
SG11201503412RA
(en)
|
2012-11-01 |
2015-05-28 |
Abbvie Inc |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
AU2014223348B2
(en)
|
2013-03-01 |
2018-12-13 |
Astex Pharmaceuticals, Inc. |
Drug combinations
|
JP6739329B2
(ja)
|
2013-03-14 |
2020-08-12 |
アボット・ラボラトリーズAbbott Laboratories |
Hcvコア脂質結合ドメインモノクローナル抗体
|
MX2015012922A
(es)
|
2013-03-14 |
2016-04-04 |
Ren Liu |
Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
|
MX2015012824A
(es)
|
2013-03-14 |
2016-06-24 |
Abbott Lab |
Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
|
BR112015023239A8
(pt)
|
2013-03-14 |
2018-04-17 |
Abbott Lab |
ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
JP6581572B2
(ja)
|
2013-06-07 |
2019-09-25 |
デューク ユニバーシティ |
補体因子h阻害薬
|
SI3444271T1
(sl)
|
2013-08-08 |
2022-03-31 |
Cytune Pharma |
Modulokini na osnovi IL-15 in IL-15Ralfa sushi domene
|
JP6794255B2
(ja)
|
2013-08-08 |
2020-12-02 |
サイチューン ファーマ |
組合せ医薬組成物
|
ES2947575T3
(es)
|
2013-09-20 |
2023-08-11 |
Bristol Myers Squibb Co |
Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores
|
ES2715890T3
(es)
|
2013-11-01 |
2019-06-06 |
Pfizer |
Vectores de expresión de antígenos asociados a la próstata
|
MX2016005925A
(es)
|
2013-11-05 |
2016-11-28 |
Cognate Bioservices Inc |
Combinaciones de inhibidores de punto de regulacion y terapeuticos para tratar el cancer.
|
US20160264670A1
(en)
|
2013-11-06 |
2016-09-15 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
CA2936611A1
(en)
|
2014-01-13 |
2015-07-16 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
NZ726513A
(en)
|
2014-05-28 |
2023-07-28 |
Memorial Sloan Kettering Cancer Center |
Anti-gitr antibodies and methods of use thereof
|
RS59643B1
(sr)
|
2014-06-06 |
2020-01-31 |
Bristol Myers Squibb Co |
Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena
|
CN105296433B
(zh)
*
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
HUE043847T2
(hu)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
|
AU2015318018B2
(en)
|
2014-09-16 |
2017-05-11 |
Synermore Biologics (Suzhou) Co. Ltd. |
Anti-EGFR antibody and uses of same
|
ES2908056T3
(es)
|
2014-10-10 |
2022-04-27 |
Idera Pharmaceuticals Inc |
Tratamiento del cáncer por agonistas del TLR9 con inhibidores del punto de control
|
NZ746680A
(en)
|
2014-10-14 |
2020-07-31 |
Halozyme Inc |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
CN107074976B
(zh)
*
|
2014-11-04 |
2020-10-09 |
北京韩美药品有限公司 |
同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白
|
WO2016074580A1
(zh)
*
|
2014-11-14 |
2016-05-19 |
中国科学院上海生命科学研究院 |
一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
|
CN113773388A
(zh)
|
2014-11-21 |
2021-12-10 |
百时美施贵宝公司 |
抗cd73抗体及其用途
|
CN107250157B
(zh)
|
2014-11-21 |
2021-06-29 |
百时美施贵宝公司 |
包含修饰的重链恒定区的抗体
|
SG11201704343SA
(en)
|
2014-12-04 |
2017-06-29 |
Bristol Myers Squibb Co |
Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
|
CN104387453A
(zh)
*
|
2014-12-08 |
2015-03-04 |
深圳市同康生物医药有限公司 |
树突状细胞靶向肽及编码基因及应用
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
TWI708786B
(zh)
|
2014-12-23 |
2020-11-01 |
美商必治妥美雅史谷比公司 |
針對tigit之抗體
|
WO2016109310A1
(en)
|
2014-12-31 |
2016-07-07 |
Checkmate Pharmaceuticals, Llc |
Combination tumor immunotherapy
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
US10202453B2
(en)
*
|
2015-02-13 |
2019-02-12 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind CTLA4
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
US10376535B2
(en)
|
2015-03-26 |
2019-08-13 |
University Of Rochester |
Therapy for malignant disease
|
TWI738646B
(zh)
|
2015-04-07 |
2021-09-11 |
日商賽多利克公司 |
醫藥組成物
|
CA2984975A1
(en)
|
2015-05-06 |
2016-11-10 |
Snipr Technologies Limited |
Altering microbial populations & modifying microbiota
|
WO2016191397A1
(en)
|
2015-05-22 |
2016-12-01 |
Td2 Inc. |
Benzamide and active compound compositions and methods of use
|
PE20180193A1
(es)
|
2015-05-29 |
2018-01-26 |
Abbvie Inc |
Anticuerpos anti-cd40 y sus usos
|
HUE061253T2
(hu)
|
2015-05-29 |
2023-06-28 |
Bristol Myers Squibb Co |
Antitestek OX40 ellen és azok felhasználásai
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
MX2017016502A
(es)
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
HRP20211478T1
(hr)
|
2015-06-29 |
2021-12-24 |
Bristol-Myers Squibb Company |
Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka
|
WO2017004538A1
(en)
|
2015-07-02 |
2017-01-05 |
Otsuka Pharmaceutical Co., Ltd. |
Lyophilized pharmaceutical compositions
|
CN111375066B
(zh)
|
2015-07-16 |
2023-04-25 |
百欧肯治疗有限公司 |
治疗癌症的组合物及方法
|
KR20180036974A
(ko)
|
2015-07-16 |
2018-04-10 |
바이오엑셀 테라퓨틱스 인코포레이티드 |
면역조절을 이용하는 암의 치료를 위한 신규한 접근법
|
US20180222990A1
(en)
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
SI3370733T1
(sl)
|
2015-11-02 |
2021-11-30 |
Board Of Regents The University Of Texas System |
Postopek za aktivacijo CD40 in blokada imunske nadzorne točke
|
JP2019503985A
(ja)
|
2015-11-03 |
2019-02-14 |
グリコミメティクス, インコーポレイテッド |
モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法
|
CN108884159A
(zh)
|
2015-11-07 |
2018-11-23 |
茂体外尔公司 |
用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
|
CN108738324B
(zh)
|
2015-11-19 |
2022-06-21 |
百时美施贵宝公司 |
抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
|
CA3007233A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
CR20180318A
(es)
|
2015-12-14 |
2018-09-19 |
Macrogenics Inc |
Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
AU2017228470A1
(en)
|
2016-03-04 |
2018-08-30 |
Bristol-Myers Squibb Company |
Combination therapy with anti-CD73 antibodies
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
EP3429693B1
(en)
|
2016-03-15 |
2023-08-23 |
Mersana Therapeutics, Inc. |
Napi2b-targeted antibody-drug conjugates and methods of use thereof
|
JP7189021B2
(ja)
|
2016-03-16 |
2022-12-13 |
アマル セラピューティクス エスエー |
医療において使用するための、免疫チェックポイントモジュレータと、細胞透過性ペプチド、カーゴ、及びtlrペプチドアゴニストを含む複合体との組合せ
|
EP3436480A4
(en)
|
2016-03-30 |
2019-11-27 |
Musc Foundation for Research Development |
METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
MA44723A
(fr)
|
2016-04-18 |
2019-02-27 |
Celldex Therapeutics Inc |
Anticorps agonistes se liant au cd40 humain et leurs utilisations
|
WO2017189976A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Targeted measure of transcriptional activity related to hormone receptors
|
US20190298824A1
(en)
|
2016-05-04 |
2019-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
AU2017268399B2
(en)
|
2016-05-18 |
2023-01-12 |
Modernatx, Inc. |
mRNA combination therapy for the treatment of cancer
|
WO2017210181A1
(en)
|
2016-05-30 |
2017-12-07 |
Geovax Inc. |
Compositions and methods for generating an immune response to hepatitis b virus
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
TWI784957B
(zh)
|
2016-06-20 |
2022-12-01 |
英商克馬伯有限公司 |
免疫細胞介素
|
CN109983121A
(zh)
|
2016-06-30 |
2019-07-05 |
昂克诺斯公司 |
治疗性多肽的假型化溶瘤病毒递送
|
PE20190418A1
(es)
|
2016-07-14 |
2019-03-19 |
Bristol Myers Squibb Co |
Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
|
NL2017270B1
(en)
*
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
WO2018025221A1
(en)
|
2016-08-04 |
2018-02-08 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-icos and anti-pd-1 antibody combination therapy
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
IL265479B
(en)
|
2016-09-21 |
2022-09-01 |
Amal Therapeutics Sa |
A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy
|
KR102530297B1
(ko)
|
2016-09-27 |
2023-05-10 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
|
MX2019003473A
(es)
|
2016-10-03 |
2019-10-15 |
Abbott Lab |
Metodos mejorados para evaluar el estado de ubiquitin carboxi-terminal hidrolasa l1 (uch-l1) en muestras de pacientes.
|
JP6976322B2
(ja)
*
|
2016-10-10 |
2021-12-08 |
クラウン バイオサイエンス,インコーポレイテッド(タイツァン) |
新規抗ctla4抗体
|
EP3527216B1
(en)
|
2016-10-11 |
2024-02-14 |
NEC Corporation |
A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide
|
CN116672456A
(zh)
|
2016-10-12 |
2023-09-01 |
得克萨斯州大学系统董事会 |
用于tusc2免疫治疗的方法和组合物
|
US20190315865A1
(en)
|
2016-10-28 |
2019-10-17 |
Bristol-Myers Squibb Company |
Methods of treating urothelial carcinoma using an anti-pd-1 antibody
|
US11124570B2
(en)
|
2016-11-08 |
2021-09-21 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-PD1 and anti-CTLA4 antibodies
|
EP3538112A4
(en)
|
2016-11-09 |
2020-09-02 |
Musc Foundation for Research Development |
CD38-NAD + REGULATED METABOLIC AXIS IN ANTITUMOR IMMUNOTHERAPY
|
EP3538152A4
(en)
|
2016-11-09 |
2020-09-30 |
Agenus Inc. |
ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF
|
US10780080B2
(en)
|
2016-11-23 |
2020-09-22 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
WO2018099539A1
(en)
|
2016-11-29 |
2018-06-07 |
Horst Lindhofer |
Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
|
WO2018100535A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
EP3548069A1
(en)
|
2016-12-01 |
2019-10-09 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
WO2018110515A1
(ja)
|
2016-12-12 |
2018-06-21 |
第一三共株式会社 |
抗体-薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
CN110545844A
(zh)
*
|
2017-02-21 |
2019-12-06 |
瑞美德生物医药科技有限公司 |
使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗
|
JP7162398B2
(ja)
|
2017-02-24 |
2022-10-28 |
ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム |
早期膵がん検出アッセイ
|
EP3366703B1
(en)
|
2017-02-28 |
2019-04-03 |
Ralf Kleef |
Immune checkpoint therapy with hyperthermia
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
WO2018167778A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of diagnosing and prognosing cancer
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
CA3052513A1
(en)
|
2017-03-23 |
2018-09-27 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
|
KR20190133213A
(ko)
|
2017-03-31 |
2019-12-02 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
JP7344797B2
(ja)
|
2017-04-15 |
2023-09-14 |
アボット・ラボラトリーズ |
早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
|
CN110621341A
(zh)
|
2017-04-26 |
2019-12-27 |
百时美施贵宝公司 |
使二硫键还原最小化的抗体生产方法
|
CN110603449A
(zh)
|
2017-04-28 |
2019-12-20 |
雅培实验室 |
用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
JP7173993B2
(ja)
*
|
2017-05-19 |
2022-11-17 |
ウーシー バイオロジクス(シャンハイ)カンパニー リミテッド |
細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対する新規モノクローナル抗体
|
CN116478289A
(zh)
*
|
2017-05-19 |
2023-07-25 |
上海药明生物技术有限公司 |
一种新的ctla-4单克隆抗体
|
CN110651190A
(zh)
|
2017-05-25 |
2020-01-03 |
雅培实验室 |
用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
|
CN116333129A
(zh)
|
2017-05-25 |
2023-06-27 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
KR20200010500A
(ko)
|
2017-05-30 |
2020-01-30 |
브리스톨-마이어스 스큅 컴퍼니 |
항-lag-3 항체, pd-1 경로 억제제, 및 면역요법제의 조합을 포함하는 조성물
|
EP3631454B1
(en)
|
2017-05-30 |
2023-09-13 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
MX2019012076A
(es)
|
2017-05-30 |
2019-12-09 |
Bristol Myers Squibb Co |
Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
|
AU2018275235A1
(en)
|
2017-05-30 |
2019-10-31 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
|
KR20200015717A
(ko)
|
2017-06-09 |
2020-02-12 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용
|
EP3649474A1
(en)
|
2017-07-03 |
2020-05-13 |
Abbott Laboratories |
Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
|
PE20200616A1
(es)
|
2017-07-14 |
2020-03-11 |
Pfizer |
ANTICUERPOS CONTRA MAdCAM
|
NZ761519A
(en)
|
2017-07-14 |
2023-07-28 |
Innate Tumor Immunity Inc |
Nlrp3 modulators
|
TWI799432B
(zh)
*
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
RU2020108580A
(ru)
|
2017-08-03 |
2021-09-03 |
Оцука Фармасьютикал Ко., Лтд. |
Лекарственное соединение и способы его очистки
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
ANTI-CD137 MOLECULES AND THEIR USE
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
US20200239577A1
(en)
|
2017-10-15 |
2020-07-30 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
CN111542544A
(zh)
|
2017-11-01 |
2020-08-14 |
百时美施贵宝公司 |
用于治疗癌症的免疫刺激性激动性抗体
|
US11638760B2
(en)
|
2017-11-27 |
2023-05-02 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
CN108003238B
(zh)
*
|
2017-11-30 |
2021-02-02 |
常州费洛斯药业科技有限公司 |
一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途
|
WO2019113525A2
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
WO2019112860A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
|
EP4295915A2
(en)
*
|
2017-12-20 |
2023-12-27 |
Harbour Biomed (Shanghai) Co., Ltd |
Antibodies binding ctla-4 and uses thereof
|
CN111757757A
(zh)
|
2017-12-21 |
2020-10-09 |
梅尔莎纳医疗公司 |
吡咯并苯并二氮呯抗体共轭物
|
KR20200103761A
(ko)
|
2017-12-27 |
2020-09-02 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd40 항체 및 그의 용도
|
JP2021508477A
(ja)
|
2017-12-29 |
2021-03-11 |
オンコラス, インコーポレイテッド |
治療用ポリペプチドの腫瘍溶解性ウイルス送達
|
CN111886255A
(zh)
|
2018-01-12 |
2020-11-03 |
百时美施贵宝公司 |
抗tim3抗体及其用途
|
JP2021511344A
(ja)
|
2018-01-22 |
2021-05-06 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
癌を治療する組成物および方法
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
US20210030703A1
(en)
|
2018-03-12 |
2021-02-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
|
WO2019177690A1
(en)
|
2018-03-12 |
2019-09-19 |
Zoetis Services Llc |
Anti-ngf antibodies and methods thereof
|
WO2019179388A1
(en)
*
|
2018-03-19 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel anti-ctla-4 antibody polypeptide
|
WO2020036635A2
(en)
|
2018-03-19 |
2020-02-20 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
|
TW201945393A
(zh)
|
2018-03-21 |
2019-12-01 |
美商戊瑞治療有限公司 |
在酸性pH結合至VISTA之抗體
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
BR112020019418A2
(pt)
|
2018-03-25 |
2021-02-17 |
Snipr Biome Aps. |
tratamento e prevenção de infecções microbianas
|
WO2019191676A1
(en)
|
2018-03-30 |
2019-10-03 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
CN112105645A
(zh)
|
2018-04-18 |
2020-12-18 |
Xencor股份有限公司 |
Il-15/il-15ra异二聚体fc融合蛋白及其用途
|
MX2020011234A
(es)
|
2018-04-25 |
2020-11-11 |
Innate Tumor Immunity Inc |
Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3).
|
EP3810109A4
(en)
|
2018-05-31 |
2022-03-16 |
Peloton Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR INHIBITING CD73
|
SG11202100096XA
(en)
|
2018-07-09 |
2021-02-25 |
Five Prime Therapeutics Inc |
Antibodies binding to ilt4
|
CA3104536A1
(en)
|
2018-07-11 |
2020-01-16 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
CA3176812A1
(en)
|
2018-07-11 |
2020-01-16 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
EP3823673A4
(en)
|
2018-07-20 |
2022-05-11 |
Surface Oncology, Inc. |
ANTI-CD112R COMPOSITIONS AND METHODS
|
AU2019321470A1
(en)
|
2018-08-16 |
2021-04-01 |
Innate Tumor Immunity, Inc. |
Substitued 4-amino-1H-Imidazo[4,5-C]Quinoline Compounds And Improved Methods For Their Preparation
|
WO2020037091A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
EP3837015B1
(en)
|
2018-08-16 |
2024-02-14 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
EP3617230A1
(en)
|
2018-09-03 |
2020-03-04 |
BioInvent International AB |
Novel antibodies and nucleotide sequences, and uses thereof
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
JP2022511337A
(ja)
|
2018-09-19 |
2022-01-31 |
インサーム (インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル) |
免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
|
CA3098765A1
(en)
|
2018-09-21 |
2020-03-26 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel interleukin-2 and use thereof
|
CN112105633B
(zh)
|
2018-09-21 |
2024-03-12 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
US20220040183A1
(en)
|
2018-10-01 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
WO2020076969A2
(en)
|
2018-10-10 |
2020-04-16 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
MA53862A
(fr)
|
2018-10-12 |
2022-01-19 |
Xencor Inc |
Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
|
KR20210081384A
(ko)
|
2018-10-23 |
2021-07-01 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
CA3117050A1
(en)
|
2018-10-29 |
2020-05-07 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
PE20211284A1
(es)
|
2018-11-16 |
2021-07-19 |
Bristol Myers Squibb Co |
Anticuerpos anti-nkg2a y usos de los mismos
|
US20220033848A1
(en)
|
2018-11-19 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
WO2020112781A1
(en)
|
2018-11-28 |
2020-06-04 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
US20220018828A1
(en)
|
2018-11-28 |
2022-01-20 |
Inserm (Institut National De La Santé Et La Recherche Médicale |
Methods and kit for assaying lytic potential of immune effector cells
|
AU2019386140A1
(en)
|
2018-11-28 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
US20220033778A1
(en)
|
2018-11-29 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
US20220018835A1
(en)
|
2018-12-07 |
2022-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
US10952996B2
(en)
|
2018-12-11 |
2021-03-23 |
Theravance Biopharma R&D Ip, Llc |
ALK5 inhibitors
|
EP3897624A1
(en)
|
2018-12-17 |
2021-10-27 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of sulconazole as a furin inhibitor
|
CA3124773A1
(en)
|
2018-12-28 |
2020-07-02 |
Transgene |
M2-defective poxvirus
|
ES2930151T3
(es)
|
2019-01-14 |
2022-12-07 |
Innate Tumor Immunity Inc |
Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer
|
CN113286786A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
JP7373571B2
(ja)
|
2019-01-14 |
2023-11-02 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
がん治療に用いるためのnlrp3モジュレーターとしての置換キナゾリン
|
KR20210114983A
(ko)
|
2019-01-14 |
2021-09-24 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Nlrp3 조정제
|
SG11202107606VA
(en)
|
2019-01-15 |
2021-08-30 |
Inst Nat Sante Rech Med |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
KR20220007850A
(ko)
|
2019-03-13 |
2022-01-19 |
이더알엔에이 이뮤노테라피스 엔브이 |
Mrna 백신
|
JP2022527177A
(ja)
|
2019-03-28 |
2022-05-31 |
ブリストル-マイヤーズ スクイブ カンパニー |
腫瘍を処置する方法
|
EP3946628A1
(en)
|
2019-03-28 |
2022-02-09 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
US20220177978A1
(en)
|
2019-04-02 |
2022-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
US20220160692A1
(en)
|
2019-04-09 |
2022-05-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
US20220220480A1
(en)
|
2019-04-17 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
CA3138348A1
(en)
|
2019-05-09 |
2020-11-12 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
CA3139162A1
(en)
|
2019-05-17 |
2020-11-26 |
Cancer Prevention Pharmaceuticals, Inc. |
Methods for treating familial adenomatous polyposis
|
KR20220016157A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 국재화 시그너쳐 및 조합 요법
|
KR20220016155A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
|
EP3976831A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures for suitability to immuno-oncology therapy
|
US20220298225A1
(en)
|
2019-06-03 |
2022-09-22 |
The University Of Chicago |
Methods and compositions for treating cancer with collagen binding drug carriers
|
AU2020286523A1
(en)
|
2019-06-03 |
2022-02-03 |
The University Of Chicago |
Methods and compositions for treating cancer with cancer-targeted adjuvants
|
US11246906B2
(en)
|
2019-06-11 |
2022-02-15 |
Alkermes Pharma Ireland Limited |
Compositions and methods for subcutaneous administration of cancer immunotherapy
|
KR20220061946A
(ko)
|
2019-06-27 |
2022-05-13 |
이더알엔에이 이뮤노테라피스 엔브이 |
병용 요법
|
CA3138188A1
(en)
|
2019-07-02 |
2021-01-07 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
EP3999539A1
(en)
|
2019-07-15 |
2022-05-25 |
Intervet International B.V. |
Caninized antibodies to human and canine ctla-4
|
CN114174337A
(zh)
|
2019-07-15 |
2022-03-11 |
英特维特国际股份有限公司 |
针对犬ctla-4的犬源化抗体
|
JPWO2021024742A1
(et)
*
|
2019-08-06 |
2021-02-11 |
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
CN114761386A
(zh)
|
2019-09-17 |
2022-07-15 |
比亚尔R&D投资股份公司 |
作为酸性神经酰胺酶抑制剂的经取代n-杂环甲酰胺及其作为药物的用途
|
KR20220100860A
(ko)
|
2019-09-17 |
2022-07-18 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
질병의 치료에 사용하기 위한 치환된, 포화 및 불포화 n-헤테로시클릭 카르복사미드 및 관련 화합물
|
US20220411388A1
(en)
|
2019-09-17 |
2022-12-29 |
Bial - R&D Investments, S.A. |
Substituted imidazole carboxamides and their use in the treatment of medical disorders
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
KR20220066334A
(ko)
|
2019-09-22 |
2022-05-24 |
브리스톨-마이어스 스큅 컴퍼니 |
Lag-3 길항제 요법에 대한 정량적 공간 프로파일링
|
BR112022004302A2
(pt)
|
2019-09-25 |
2022-06-21 |
Surface Oncology Inc |
Anticorpos anti-il-27 e usos dos mesmos
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
WO2021067863A2
(en)
|
2019-10-03 |
2021-04-08 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
EP4049675A4
(en)
|
2019-10-25 |
2023-11-22 |
Daiichi Sankyo Company, Limited |
COMBINATION OF ANTI-GARP ANTIBODY AND IMMUNOREGULATOR
|
US20220380765A1
(en)
|
2019-11-02 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
US20220411499A1
(en)
|
2019-11-08 |
2022-12-29 |
Bristol-Myers Squibb Company |
LAG-3 Antagonist Therapy for Melanoma
|
EP4061809A1
(en)
|
2019-11-22 |
2022-09-28 |
Theravance Biopharma R&D IP, LLC |
Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
|
JPWO2021106978A1
(et)
|
2019-11-27 |
2021-06-03 |
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
IL294085A
(en)
|
2019-12-19 |
2022-08-01 |
Bristol Myers Squibb Co |
Combinations of dgk inhibitors and checkpoint antagonists
|
US20230058982A1
(en)
|
2019-12-27 |
2023-02-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody and use thereof
|
JP2023509516A
(ja)
|
2020-01-07 |
2023-03-08 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
がん治療のための改良型ヒトメチルチオアデノシン/アデノシン枯渇酵素変種
|
EP4087842A1
(en)
|
2020-01-10 |
2022-11-16 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
IL295387A
(en)
|
2020-02-05 |
2022-10-01 |
Larimar Therapeutics Inc |
Peptide-binding proteins and their uses
|
JP2023514152A
(ja)
|
2020-02-06 |
2023-04-05 |
ブリストル-マイヤーズ スクイブ カンパニー |
Il-10およびその使用
|
CA3168337A1
(en)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
US20230045494A1
(en)
|
2020-02-28 |
2023-02-09 |
Orega Biotech |
Combination therapies based on ctla4 and il-17b inhibitors
|
AU2021357520A1
(en)
|
2020-03-05 |
2022-09-29 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
US20230140384A1
(en)
|
2020-03-09 |
2023-05-04 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
TW202204339A
(zh)
|
2020-03-31 |
2022-02-01 |
美商施萬生物製藥研發 Ip有限責任公司 |
經取代的嘧啶及使用方法
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
CA3175499A1
(en)
|
2020-04-21 |
2021-10-28 |
University Of Rochester |
Inhibitors of human epididymus protein 4
|
IL297442A
(en)
|
2020-04-22 |
2022-12-01 |
Iovance Biotherapeutics Inc |
Systems and methods for coordinating production of cells for patient-specific immunotherapy
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
US20230212256A1
(en)
|
2020-05-21 |
2023-07-06 |
Board Of Regents, The University Of Texas System |
T cell receptors with vgll1 specificity and uses thereof
|
CN115768885A
(zh)
|
2020-06-03 |
2023-03-07 |
Mv生物治疗股份有限公司 |
Atp水解酶和免疫检查点调节剂的组合及其应用
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
EP4161653A1
(en)
|
2020-06-03 |
2023-04-12 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
WO2021253041A1
(en)
|
2020-06-10 |
2021-12-16 |
Theravance Biopharma R&D Ip, Llc |
Naphthyridine derivatives useful as alk5 inhibitors
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
AU2021302958A1
(en)
|
2020-06-30 |
2023-02-16 |
Mendus B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
EP4178678A1
(en)
|
2020-07-07 |
2023-05-17 |
Cancure, LLC |
Mic antibodies and binding agents and methods of using the same
|
IL298993A
(en)
|
2020-07-07 |
2023-02-01 |
BioNTech SE |
Therapeutic RNA for HPV positive cancer
|
EP4185322A2
(en)
|
2020-07-24 |
2023-05-31 |
Amgen Inc. |
Immunogens derived from sars-cov2 spike protein
|
US20230295146A1
(en)
|
2020-07-24 |
2023-09-21 |
The University Of Rochester |
Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
|
EP4193149A1
(en)
|
2020-08-04 |
2023-06-14 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
CN112359052B
(zh)
*
|
2020-08-20 |
2023-01-03 |
山东兴瑞生物科技有限公司 |
抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用
|
MX2023002332A
(es)
|
2020-08-28 |
2023-03-21 |
Bristol Myers Squibb Co |
Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular.
|
JP2023538955A
(ja)
|
2020-08-31 |
2023-09-12 |
ブリストル-マイヤーズ スクイブ カンパニー |
細胞局在シグネチャーおよび免疫療法
|
EP4232019A1
(en)
|
2020-10-23 |
2023-08-30 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
CA3201499A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
EP4251645A1
(en)
|
2020-11-25 |
2023-10-04 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
US20220170948A1
(en)
|
2020-12-01 |
2022-06-02 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
US20220218614A1
(en)
|
2020-12-04 |
2022-07-14 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
EP4259658A1
(en)
*
|
2020-12-10 |
2023-10-18 |
Wuxi Biologics Ireland Limited |
An antibody against p-cadherin and uses thereof
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
CA3206304A1
(en)
|
2020-12-24 |
2022-06-30 |
Vib Vzw |
Human ccr8 binders
|
US20240052044A1
(en)
|
2020-12-24 |
2024-02-15 |
Vib Vzw |
Non-blocking human ccr8 binders
|
EP4267621A1
(en)
|
2020-12-24 |
2023-11-01 |
Vib Vzw |
Murine cross-reactive human ccr8 binders
|
CA3201348A1
(en)
|
2020-12-28 |
2022-07-07 |
Masano HUANG |
Antibody compositions and methods of use thereof
|
EP4267172A1
(en)
|
2020-12-28 |
2023-11-01 |
Bristol-Myers Squibb Company |
Subcutaneous administration of pd1/pd-l1 antibodies
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
EP4281116A1
(en)
|
2021-01-19 |
2023-11-29 |
William Marsh Rice University |
Bone-specific delivery of polypeptides
|
JP2024506249A
(ja)
|
2021-01-22 |
2024-02-13 |
メンドゥス・ベスローテン・フェンノートシャップ |
腫瘍ワクチン接種の方法
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
EP4070799A1
(en)
|
2021-04-08 |
2022-10-12 |
Nuvamid SA |
Compositions for the improvement of sport performance
|
WO2022217022A1
(en)
|
2021-04-10 |
2022-10-13 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
EP4079311A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
|
WO2022223622A1
(en)
|
2021-04-20 |
2022-10-27 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
EP4079310A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
CA3216320A1
(en)
|
2021-05-18 |
2022-11-24 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
WO2022266034A1
(en)
|
2021-06-14 |
2022-12-22 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
IL308633A
(en)
|
2021-06-25 |
2024-01-01 |
Chugai Pharmaceutical Co Ltd |
Use of anti-CTLA-4 antibodies
|
CN117616123A
(zh)
|
2021-06-25 |
2024-02-27 |
中外制药株式会社 |
抗ctla-4抗体
|
WO2023280790A1
(en)
|
2021-07-05 |
2023-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
WO2023285552A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
CA3228262A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
CA3229448A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
CA3230038A1
(en)
|
2021-08-31 |
2023-03-09 |
Hongwei Zhang |
Methods and systems of diagnosing brain injury
|
AU2022354059A1
(en)
|
2021-09-30 |
2024-03-28 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023060136A1
(en)
|
2021-10-05 |
2023-04-13 |
Cytovia Therapeutics, Llc |
Natural killer cells and methods of use thereof
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
CA3224890A1
(en)
|
2021-10-29 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
WO2023097024A1
(en)
*
|
2021-11-24 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
TW202332687A
(zh)
|
2021-12-23 |
2023-08-16 |
比利時商eTheRNA免疫治療公司 |
免疫刺激性mrna組成物及其用途
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023147371A1
(en)
|
2022-01-26 |
2023-08-03 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023164638A1
(en)
|
2022-02-25 |
2023-08-31 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2023240156A1
(en)
|
2022-06-08 |
2023-12-14 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024003353A1
(en)
|
2022-07-01 |
2024-01-04 |
Transgene |
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|